靶向肾素-血管紧张素系统以改善癌症治疗：免疫治疗的意义。
Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy.
机构信息
Edwin L. Steele Laboratories for Tumor Biology, Department of Radiation Oncology, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114, USA.
Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, A-1090, Austria.
出版信息
Sci Transl Med. 2017 Oct 4;9(410). doi: 10.1126/scitranslmed.aan5616.
Renin-angiotensin system (RAS) inhibitors (RASi)-widely prescribed for the treatment of cardiovascular diseases-have considerable potential in oncology. The RAS plays a crucial role in cancer biology and affects tumor growth and dissemination directly and indirectly by remodeling the tumor microenvironment. We review clinical data on the benefit of RASi in primary and metastatic tumors and propose that, by activating immunostimulatory pathways, these inhibitors can enhance immunotherapy of cancer.
肾素-血管紧张素系统（RAS）抑制剂（RASi）广泛用于治疗心血管疾病，在肿瘤学方面具有巨大的潜力。RAS 在癌症生物学中起着至关重要的作用，通过重塑肿瘤微环境，直接和间接地影响肿瘤的生长和扩散。我们回顾了 RASi 在原发性和转移性肿瘤中的临床获益数据，并提出这些抑制剂通过激活免疫刺激途径，可以增强癌症的免疫治疗。
Zotero 插件